• PDF / 169,200 Bytes
• 1 Pages / 595.245 x 841.846 pts (A4) Page_size
• 16 Downloads / 168 Views

DOWNLOAD

REPORT

---

1 S

Corrected QT-interval prolongation following off label use: case report In an observational case-control study of 22 patients treated during March 2020 in Italy, a patient [age and sex not stated] was described, who developed corrected QT-interval (QTc) prolongation following off label use of azithromycin and hydroxychloroquine for coronavirus disease 2019 (COVID-19). The patient, who was diagnosed with COVID-19, was admitted to a hospital and started receiving off label treatment with oral hydroxychloroquine 200mg, twice daily (at 8am and 8pm, daily) and azithromycin 500mg, once daily over a period of at least three days. A 12-lead ECG, at least three days after the initiation of azithromycin and hydroxychloroquine, revealed prolongation of QTc with a value noted as >500 ms [outcome of ADR not stated]. Cipriani A, et al. Arrhythmic profile and 24-hour QT interval variability in COVID-19 patients treated with hydroxychloroquine and azithromycin. International Journal of 803503489 Cardiology 316: 280-284, Oct 2020. Available from: URL: http://doi.org/10.1016/j.ijcard.2020.05.036

0114-9954/20/1823-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved

Reactions 26 Sep 2020 No. 1823